Dr Shalini Andersson

Shalini is currently Vice President of Nucleic acid Therapeutics in BioPharmaceuticals R&D, Astrazeneca. She is also a member of the Management Team for Discovery Sciences and the Review Boards for drug projects in the Cardiovascular Renal Metabolism and Respiratory & Immunology therapy areas. Shalini has more than 25 years of research experience in the pharmaceutical industry mainly from discovery and development of small molecule therapeutics and during the last 10 years also from nucleic acid based therapeutics. She has broad experience of management of departments and teams as well as setting and delivering business strategies. Shalini is involved in several collaborations with biotech companies as well as with academic groups around the globe. Shalini received her PhD in 1989 at the University of Linköping, Sweden. Prior to joining AstraZeneca in 1997, she was Associate Professor in Organic and Analytical Chemistry at the University of Linköping, Sweden. Shalini is the author or co-author of over 65 peer reviewed articles and 6 patents. Shalini is a member of the Joint Steering Committee for the disease area collaboration with Ionis Pharma, Silence Therapeutics and JCR Pharmaceuticals focused on discovery and development of nucleic acid therapeutics. Shalini is member of the Board of Oligonucleotide Therapeutics Society and the Board of OligoNova (Sweden).